Hancock Whitney Corp Buys 451 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Hancock Whitney Corp lifted its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,408 shares of the medical instruments supplier’s stock after purchasing an additional 451 shares during the period. Hancock Whitney Corp’s holdings in West Pharmaceutical Services were worth $8,369,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in WST. Evoke Wealth LLC purchased a new stake in West Pharmaceutical Services in the fourth quarter worth about $7,770,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in West Pharmaceutical Services by 1.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock worth $75,766,000 after acquiring an additional 2,759 shares during the period. Vanguard Group Inc. lifted its stake in West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after acquiring an additional 104,740 shares during the period. Mizuho Markets Americas LLC lifted its stake in West Pharmaceutical Services by 142.3% in the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock worth $11,724,000 after acquiring an additional 17,399 shares during the period. Finally, Hsbc Holdings PLC lifted its stake in West Pharmaceutical Services by 39.8% in the fourth quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock worth $48,750,000 after acquiring an additional 39,392 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Down 1.0 %

NYSE:WST opened at $308.15 on Friday. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The company has a 50-day moving average of $303.37 and a 200 day moving average of $337.42. The firm has a market cap of $22.45 billion, a PE ratio of 40.65, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same period last year, the company earned $2.11 earnings per share. The firm’s revenue was down 6.9% compared to the same quarter last year. As a group, research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.